At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 134 enrolled
Drug / intervention
pridopidinedrug
Likely dose
pridopidine 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).
In Brief
A Phase 2 clinical trial evaluating pridopidine for Huntington Disease. Completed, enrolled 134 participants.
Detailed Summary
Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartMar 2011
Primary CompletionJan 2018
TodayJul 2026
First PostedMar 2, 2011
Enrollment StartMar 24, 2011
Primary CompletionJan 5, 2018
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 15.3 years ago
Interventions
pridopidinedrug
45mg bid